Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CT010
- Development stage
- Preclinical
- Lead developer
- Cerebral Therapeutics
- Administration
- Ophthalmic
01
Overview
CT010 is a preclinical-stage therapeutic candidate under development by Clover Therapeutics for the treatment of age-related macular degeneration (AMD), including both the dry (non-exudative) and wet (exudative) forms. Clover Therapeutics utilizes a genetics-driven research and development approach, leveraging data from observational studies such as DIVERSITY and PROGRESSION to identify novel drug targets. As of the current pipeline reports, the specific molecular target, mechanism of action, and modality of CT010 remain undisclosed by the developer.
Beyond the preview
Go deeper on CT010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CT010.